BeVigilant™ OraFusion™ System**
Granted FDA Breakthrough Device Designation
The BeVigilant™ OraFusion™ System** is Not Available For Sale in the U.S.
The BeVigilant™ OraFusion™ System** identifies the presence of biomarkers associated with oral cancer in 15 minutes or less.
BeVigilant™ OraFusion™ System**
With the BeVigilant™ OraFusion™ System, clinicians can get a simple and accurate* assessment to aid in the early detection of oral cancer. The platform provides a semi-quantitative result at the point–of–care, reporting low, moderate or elevated levels of risk associated with oral cancer. Learn how it benefits dentists and their patients:
BeVigilant™ OraFusion™ Test Output: Biomarkers + Clinical Risk Factors
How the BeVigilant™ OraFusion™ System** Works
BeVigilant™ OraFusion™ System is an easy-to-use, accurate*, semi-quantitative tool for frontline healthcare clinicians assessing potentially at-risk patients for oral cancer.
The BeVigilant™ Reader is an advanced immunochromatography reader which captures the test data and provides the results during the patient’s visit.
Created to improve outcomes through earlier intervention, the BeVigilant™ OraFusion™ System** is
ACCURATE*
Using multiple biomarkers in conjunction with clinical risk factors provides an accurate risk assessment
NON-INVASIVE
Simple saliva test
Fast
Results in just 15 minutes or less
The BeVigilant™ OraFusion™ System is patent pending and available in select markets outside the United States. Interested in learning more about the technology’s availability in your market?
Schedule a demo to discover if the BeVigilant OraFusion System is right for your practice.
*Clinical Data on File
EN 
IT 
DE 
TR 
PT 
NL 
FR 
ES